Dr. Janet Chollet

Co-Founder and Chief Medical Officer of Procyrn LLC


Dr. Janet A. Chollet is a board-certified obstetrician–gynecologist, biotech co-founder, and translational medicine leader based in Boston. She is the Co-Founder and Chief Medical Officer of Procyrn LLC, where she directs efforts on sustained-release hydrogel immune therapeutics and reformulated antivirals. Her work centers on advancing treatments for maternal–fetal health, neuroinflammation, and HPV-related cervical disease.


With over thirty years of experience in both clinical and academic roles, Dr. Janet Chollet has served at respected institutions, including Beth Israel Deaconess Medical Center and the University of Pittsburgh. She is also an inventor, holding three U.S. patents in women’s health drug delivery. Over her career, she has guided several preclinical and early clinical programs, combining patient care with translational research and innovation.


Early Education and Medical Foundation


Janet Chollet began her academic path at the University of California, Santa Barbara, where she earned a Bachelor of Science in Neuroscience in 1986. Her interest in how science could be applied to improve health led her to pursue a Doctor of Medicine at New York Medical College, which she completed in 1991.


Following medical school, she entered residency at LAC/USC Women’s Hospital, where she trained in Obstetrics and Gynecology from 1991 through 1995. This period helped shape her long-term focus on developing better therapeutic approaches for women, children, and families.


Clinical and Academic Practice


After completing residency, she joined Magee-Women’s Hospital at the University of Pittsburgh as a staff physician and instructor. From 2000 to 2007, she balanced patient care with mentoring and clinical teaching. These experiences strengthened her view of translational medicine as a bridge between clinical practice and therapeutic innovation.


In 2007, Janet Chollet MD, joined Beth Israel Deaconess Medical Center in Boston, where she continues to practice as an obstetrician–gynecologist. In addition to her clinical responsibilities, she contributes to academic training and incorporates translational research into her patient care.


Pear Tree Pharmaceuticals and Foundational IP


In 2005, she co-founded Pear Tree Pharmaceuticals, a company dedicated to site-targeted therapies for women’s health. The company focused on solutions for breast cancer survivors and women facing vulvovaginal atrophy. She served as Vice President of Clinical Affairs until 2018, where she worked on vaginal delivery technologies designed to minimize systemic exposure while addressing local symptoms for women who could not use hormone-based therapies.


Her contributions led to three issued U.S. patents in topical and vaginal drug delivery:



This intellectual property played a crucial role in supporting Pear Tree’s eventual merger with Dare Bioscience (NASDAQ: DARE), a company dedicated to developing therapies for women’s health.


Founding Procyrn LLC


In 2023, Dr. Janet co-founded Procyrn LLC, a biotechnology company in Boston. The company focuses on sustained-release biologics and reformulated antivirals. As Chief Medical Officer, she leads the clinical development process, translational planning, and regulatory strategy. Procyrn applies drug delivery science to address areas of significant unmet need, including maternal–fetal health, neuroinflammation, and HPV-driven cervical disease.


Therapeutic Programs Under Her Leadership


Maternal–Fetal Health (PC101)


The company’s lead program, PC101, focuses on preeclampsia and HELLP syndrome, severe hypertensive disorders of pregnancy that often result in preterm delivery. These conditions are estimated to carry an annual cost of $26 billion in the United States. PC101 is a sustained-release hydrogel biologic created to stabilize maternal–fetal health and reduce the need for early delivery. With preclinical validation complete, the program is advancing with collaborators including Northeastern University and Charles River Laboratories. The aim is to safely prolong pregnancy and improve health outcomes for both mothers and infants.


Neuroinflammation and ALS


Dr. Chollet's expertise in immune-modulating therapeutics has been applied to the treatment of neurodegenerative diseases. One program, developed with Jackson Laboratory, targets C9orf72-associated amyotrophic lateral sclerosis, the most common genetic form of ALS. Since neuroinflammation is a critical factor in disease progression, the work focuses on strategies to address inflammatory pathways through translational approaches.


HPV-Driven Cervical Dysplasia


Another program is aimed at nonsurgical treatment options for cervical dysplasia, which is often managed with excisional procedures that can lead to recurrence and complications. Building on similarities between vulnerabilities in p53-deficient cells and HPV oncogenic proteins, this effort advances a localized antiviral platform designed for the cervicovaginal environment. Current research, conducted in collaboration with Charles River Laboratories, focuses on in vitro validation studies.


Exploratory Program — Autism Prevention


Dr. Chollet is also exploring maternal–fetal immune therapeutics designed to lower risks of neurodevelopmental disorders such as autism. Research suggests that maternal immune activation and placental inflammation may affect fetal brain development. Preclinical studies, including those using Zika virus models, indicate that preserving placental function can protect offspring from neurodevelopmental issues. Building on this foundation, she aims to investigate pregnancy-compatible therapeutics that reduce oxidative stress and stabilize the intrauterine environment. Though still in the exploratory stage, this program reflects a broader vision of preventive maternal–fetal care.


Regulatory and Development Expertise


Her leadership also extends into regulatory planning and execution. She creates IND-enabling pathways, aligns milestones with funding cycles, and emphasizes clear go/no-go criteria. A focus on reproducibility in preclinical models is central to her approach, ensuring both scientific rigor and confidence among stakeholders.


Creative Work and Narrative Perspective


Earlier in her career, Dr. Chollet co-wrote the Emmy-winning ER episode Love’s Labor Lost. The episode earned five Emmy Awards for the series. Though Warner Bros. offered her a staff writing role, she chose to continue her path in medicine, highlighting her commitment to healthcare while maintaining her creative voice.


Personal Interests and Balance


Outside her professional responsibilities, she values family, wellness, and creativity. Dr. Janet maintains health through strength training and exercise, enjoys spending holidays with family, and appreciates the companionship of pets. Golf is another activity she finds meaningful, as it provides both focus and clarity.


Her interests also include travel, discovery, and creative writing. Recently, she has turned her attention toward exploring the role of artificial intelligence in clinical workflows and translational medicine, aiming to see how technology might help accelerate progress from research to patient care.


Dr. Janet Chollet continues to contribute to medicine, biotechnology, and translational research, combining patient care with innovation while maintaining balance through personal interests and family life.